Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001829126-26-002858 0002120637 XXXXXXXX LIVE 1 Common Stock, $0.01 par value 04/28/2026 false 0001857044 45339J105 Indaptus Therapeutics, Inc. c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY 10019 Yun Yao (646) 427-2727 c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York NY 10019 0002120637 N Yao Yun b PF N C3 41991000.00 0.00 41991000.00 0.00 41991000.00 N 37.1 IN Yun Yao beneficially owns 41,991,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement"), and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. The Reporting Persons may be deemed to constitute a "group" within the meaning of Section 13(d) of the Securities Exchange Act of 1934 solely for purposes of the Purchase Agreement and the transactions contemplated thereby. For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. All percentage calculations herein are based on 113,242,324 shares of Common Stock outstanding of the issuer as of March 31, 2026, based on information provided to the Reporting Person by the Issuer. 0002120638 N SINO LION VENTURES Ltd b WC N D8 0.00 38895000.00 0.00 38895000.00 38895000.00 N 34.3 PN Sino Lion Ventures Limited beneficially owns 38,895,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Purchase Agreement, and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. The Reporting Persons may be deemed to constitute a "group" within the meaning of Section 13(d) of the Securities Exchange Act of 1934 solely for purposes of the Purchase Agreement and the transactions contemplated thereby. For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group. The Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. All percentage calculations herein are based on 113,242,324 shares of Common Stock outstanding of the issuer as of March 31, 2026, based on information provided to the Reporting Person by the Issuer. Y Xu Chenhao b WC N X0 0.00 38895000.00 0.00 38895000.00 38895000.00 N 34.3 IN Chenhao Xu is the controlling person of Sino Lion Ventures Limited, a purchaser under the Purchase Agreement. Such shares were acquired pursuant to the Purchase Agreement, and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. The Reporting Persons may be deemed to constitute a "group" within the meaning of Section 13(d) of the Securities Exchange Act of 1934 solely for purposes of the Purchase Agreement and the transactions contemplated thereby. For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. All percentage calculations herein are based on 113,242,324 shares of Common Stock outstanding of the issuer as of March 31, 2026, based on information provided to the Reporting Person by the Issuer. 0002022463 N Dai Junyi b PF N C3 11250000.00 0.00 11250000.00 0.00 11250000.00 N 9.9 IN Junyi Dai beneficially owns 11,250,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Purchase Agreement, and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. The Reporting Persons may be deemed to constitute a "group" within the meaning of Section 13(d) of the Securities Exchange Act of 1934 solely for purposes of the Purchase Agreement and the transactions contemplated thereby. For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. All percentage calculations herein are based on 113,242,324 shares of Common Stock outstanding of the issuer as of March 31, 2026, based on information provided to the Reporting Person by the Issuer. 0002120636 N Yang Ting b PF N X0 11250000.00 0.00 11250000.00 0.00 11250000.00 N 9.9 IN Ting Yang beneficially owns 11,250,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Purchase Agreement, and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. The Reporting Persons may be deemed to constitute a "group" within the meaning of Section 13(d) of the Securities Exchange Act of 1934 solely for purposes of the Purchase Agreement and the transactions contemplated thereby. For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. All percentage calculations herein are based on 113,242,324 shares of Common Stock outstanding of the issuer as of March 31, 2026, based on information provided to the Reporting Person by the Issuer. 0002120635 N Deng Lina b PF N C3 5550000.00 0.00 5550000.00 0.00 5550000.00 N 4.9 IN Lina Deng beneficially owns 5,550,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Purchase Agreement, and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. The Reporting Persons may be deemed to constitute a "group" within the meaning of Section 13(d) of the Securities Exchange Act of 1934 solely for purposes of the Purchase Agreement and the transactions contemplated thereby. For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. All percentage calculations herein are based on 113,242,324 shares of Common Stock outstanding of the issuer as of March 31, 2026, based on information provided to the Reporting Person by the Issuer. Common Stock, $0.01 par value Indaptus Therapeutics, Inc. c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY 10019 Explanatory Note. This Amendment No. 1 to Schedule 13D (this "Amendment") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission ("SEC") on March 30, 3026 (the "Original Schedule 13D") by Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang, and Lina Deng (each, a "Reporting Person" and collectively, the "Reporting Persons"). Capitalized terms used herein and not otherwise defined shall have the respective meanings ascribed to them in the Original Schedule 13D. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Original Schedule 13D. The Amendment is being filed to clarify that the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group under the Purchase Agreement and will no longer operate as a group. In addition, this Amendment is being filed because Lina Deng has ceased to be the beneficial owner of more than five percent of the shares of Common Stock as a result of an increase in the number of shares of Common Stock outstanding of the Issuer. This Amendment is the final amendment to the Original Schedule 13D and constitutes an "exit filing" for Lina Deng. Item 2(a) of the Original Schedule 13D is amended by adding the following sentence: For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group. The information contained in rows 11 and 13 of the cover pages of this Schedule 13D (including the accompanying comments thereto) is incorporated herein by reference. The ownership information presented herein represents beneficial ownership of shares of Common Stock as of the date of this filing, based upon 113,242,324 shares of Common Stock outstanding as of March 31, 2026. The information contained in rows 7 through 10 of the cover pages of this Amendment (including the accompanying comments thereto) is incorporated herein by reference. Except as described in this Amendment, none of the Reporting Persons have effected any transaction in the shares of Common Stock during the past 60 days. No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. As a result of an increase in the number of shares of Common Stock outstanding of the Issuer, Lina Deng ceased to be the beneficial owner of more than five percent of the shares of the Issuer's Common Stock. Exhibit 1: Joint Filing Agreement, dated as of March 30, 2026, by and among Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang, and Lina Deng (incorporated by reference to Exhibit 99.2 to the Schedule 13D filed with the SEC by the Reporting Persons on March 30, 2026). https://www.sec.gov/Archives/edgar/data/1857044/000182912626002858/indaptustherap_ex99-2.htm Yao Yun /s/ Yun Yao Yun Yao 04/28/2026 SINO LION VENTURES Ltd /s/ Chenhao Xu Chenhao Xu / Authorized Signatory 04/28/2026 Xu Chenhao /s/ Chenhao Xu Chenhao Xu 04/28/2026 Dai Junyi /s/ Junyi Dai Junyi Dai 04/28/2026 Yang Ting /s/ Ting Yang Ting Yang 04/28/2026 Deng Lina /s/ Lina Deng Lina Deng 04/28/2026